PRESS RELEASE | Jul / 2024
Aspargo Labs Announces Data on First Oral Spray for Erectile Dysfunction, ASP-001, Showing Two Times Faster Absorption Compared to Viagra® Tablets
READ MORE
PRESS RELEASE | Dec / 2023
Aspargo Announces Completion of Dosing of All Subjects in Sildenafil Oral Suspension Bioavailability Study and Initiation of Dosing in Companion Food-Effect Study
READ MORE
PRESS RELEASE | Sep / 2023
Aspargo Laboratories Inc. Announces Initial Dosing of All Subjects in Bioavailability Study for Sildenafil Oral Suspension
READ MORE
PRESS RELEASE | Sep / 2023
Aspargo Laboratories Announces IND Clearance by U.S. FDA, Enabling Launch of Bioequivalence and Food-Effect Studies for Sildenafil Oral Spray
READ MORE
PRESS RELEASE | Aug / 2023
Aspargo Laboratories, Inc. Announces Filing of Its Investigational New Drug Application For Sildenafil Oral Spray
READ MORE
PRESS RELEASE | Jan / 2023
Aspargo Receives Regulatory Approval to Market Sildenafil Spray in Germany, Ireland, and The Netherlands
READ MORE
PRESS RELEASE | Nov / 2022
Aspargo Extends Latin America Reach From Mexico To Argentina
READ MORE
PRESS RELEASE | Oct / 2022
Aspargo’s Footprint Grows With Middle East Expansion
READ MORE
PRESS RELEASE | Jun / 2022
Aspargo Expands Beyond Spain Into Latin America
READ MORE
PRESS RELEASE | May / 2022
Aspargo Acquires Bandol® Sildenafil Spray
READ MORE
PRESS RELEASE | Sep / 2020
Aspargo Acquires International Rights to Sildenafil Oral Spray
READ MORE
PRESS RELEASE | May / 2020
Aspargo Announces Successful Completion of Pre-IND Meeting w/ FDA
READ MORE